The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Potential role of HER2‐overexpressing exosomes in countering trastuzumab‐based therapy
Abstract
Exosomes are endosome‐derived nanovesicles actively released into the extracellular environment and biological fluids, both under physiological and pathological conditions, by different cell types. We characterized exosomes constitutively secreted by HER2‐overexpressing breast carcinoma cell lines and analyzed in vitro and in vivo their potential role in interfering with the therapeutic activity of the humanized antibody Trastuzumab and the dual tyrosine kinase inhibitor (TKI) Lapatinib anti‐HER2 biodrugs. We show that exosomes released by the HER2‐overexpressing tumor cell lines SKBR3 and BT474 express a full‐length HER2 molecule that is also activated, although to a lesser extent than in the originating cells. Release of these exosomes was significantly modulated by the growth factors EGF and heregulin, two of the known HER2 receptor‐activating ligands and naturally present in the surrounding tumor microenvironment. Exosomes secreted either in HER2‐positive tumor cell‐conditioned supernatants or in breast cancer patients' serum bound to Trastuzumab. Functional assays revealed that both xenogeneic and autologous HER2‐positive nanovesicles, but not HER2‐negative ones, inhibited Trastuzumab activity on SKBR3 cell proliferation. By contrast, Lapatinib activity on SKBR3 cell proliferation was unaffected by the presence of autologous exosomes. Together, these findings point to the role of HER2‐positive exosomes in modulating sensitivity to Trastuzumab, and, consequently, to HER2‐driven tumor aggressiveness. J. Cell. Physiol. 227: 658–667, 2012. © 2011 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Membrane vesicles as conveyors of immune responses
Théry, C., Ostrowski, M., & Segura, E. (2009) · Nature Reviews Immunology · doi:10.1038/nri2567 · Cited by 3,882
Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells
Al-Nedawi, K., Meehan, B., Micallef, J., Lhotak, V., May, L., Guha, A., & Rak, J. (2008) · Nature Cell Biology · doi:10.1038/ncb1725 · Cited by 2,034
Exosomal-like vesicles are present in human blood plasma
Caby, M.-P., Lankar, D., Vincendeau-Scherrer, C., Raposo, G., & Bonnerot, C. (2005) · International Immunology · doi:10.1093/intimm/dxh267 · Cited by 1,343
Chalmin, F., Ladoire, S., Mignot, G., Vincent, J., Bruchard, M., Remy-Martin, J.-P., Boireau, W., Rouleau, A., Simon, B., Lanneau, D., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40483 · Cited by 998
High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients
Logozzi, M., De Milito, A., Lugini, L., Borghi, M., Calabrò, L., Spada, M., Perdicchio, M., Marino, M. L., Federici, C., Iessi, E., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005219 · Cited by 960
Self-citationMalignant effusions and immunogenic tumour-derived exosomes
Andre, F., Schartz, N. E., Movassagh, M., Flament, C., Pautier, P., Morice, P., Pomel, C., Lhomme, C., Escudier, B., Le Chevalier, T., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09552-1 · Cited by 953
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M., Ellis, C., Casey, M., Vukelja, S., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 942
Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 914
Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., Arribas, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk134 · Cited by 895
Exosome Release Is Regulated by a Calcium-dependent Mechanism in K562 Cells
Savina, A., Furlán, M., Vidal, M., & Colombo, M. I. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301642200 · Cited by 834
Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles
Andreola, G., Rivoltini, L., Castelli, C., Huber, V., Perego, P., Deho, P., Squarcina, P., Accornero, P., Lozupone, F., Lugini, L., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011624 · Cited by 774
Self-citationHuber, V., Fais, S., Iero, M., Lugini, L., Canese, P., Squarcina, P., Zaccheddu, A., Colone, M., Arancia, G., Gentile, M., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.045 · Cited by 524
Self-citationGennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, E., Castiglioni, F., Villani, L., Magalotti, C., Gibelli, N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0225 · Cited by 516
Self-citationValenti, R., Huber, V., Filipazzi, P., Pilla, L., Sovena, G., Villa, A., Corbelli, A., Fais, S., Parmiani, G., & Rivoltini, L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1819 · Cited by 493
Self-citationTumour-released exosomes and their implications in cancer immunity
Iero, M., Valenti, R., Huber, V, Filipazzi, P., Parmiani, G., Fais, S., & Rivoltini, L. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402237 · Cited by 485
Self-citationSzajnik, M., Czystowska, M., Szczepanski, M. J., Mandapathil, M., & Whiteside, T. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011469 · Cited by 462
Effect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs
Luciani, F., Spada, M., De Milito, A., Molinari, A., Rivoltini, L., Montinaro, A., Marra, M., Lugini, L., Logozzi, M., Lozupone, F., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh305 · Cited by 435
Self-citationProteomic Analysis of Exosomes Isolated from Human Malignant Pleural Effusions
Bard, M. P., Hegmans, J. P., Hemmes, A., Luider, T. M., Willemsen, R., Severijnen, L.-A. A., van Meerbeeck, J. P., Burgers, S. A., Hoogsteden, H. C., & Lambrecht, B. N. (2004) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2003-0238oc · Cited by 416
Microvesicles: Messengers and mediators of tumor progression
Al-Nedawi, K., Meehan, B., & Rak, J. (2009) · Cell Cycle · doi:10.4161/cc.8.13.8988 · Cited by 402
Weigelt, B., Lo, A. T., Park, C. C., Gray, J. W., & Bissell, M. J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0502-2 · Cited by 334
Purification, characterization and biological significance of tumor-derived exosomes.
Koga, K., Matsumoto, K., Akiyoshi, T., Kubo, M., Yamanaka, N., Tasaki, A., Nakashima, H., Nakamura, M., Kuroki, S., Tanaka, M., et al. (2005) · PubMed · Cited by 240
A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis
Pedersen, K., Angelini, P.-D., Laos, S., Bach-Faig, A., Cunningham, M. P., Ferrer-Ramón, C., Luque-García, A., García-Castillo, J., Parra-Palau, J. L., Scaltriti, M., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01803-08 · Cited by 186
Management of breast cancer with targeted agents: importance of heterogenicity
Di Cosimo, S., & Baselga, J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.234 · Cited by 161
O’Shaughnessy, J., Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Sledge, G. W., Baselga, J. M., Koehler, M. T., Laabs, S., Florance, A. M., & Roychowdhury, D. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1015 · Cited by 154
Safaei, R., Katano, K., Larson, B. J., Samimi, G., Holzer, A. K., Naerdemann, W., Tomioka, M., Goodman, M., & Howell, S. B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.756.11.2 · Cited by 141
Sanderson, M. P., Keller, S., Alonso, Á., Riedle, S., Dempsey, P. J., & Altevogt, P. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21569 · Cited by 137
Nicola, M. D., Zappasodi, R., Carlo‐Stella, C., Mortarini, R., Pupa, S. M., Magni, M., Devizzi, L. F., Matteucci, P., Baldassari, P., Ravagnani, F., et al. (2008) · Blood · doi:10.1182/blood-2008-06-165654 · Cited by 122
Self-citationTagliabue, E., Centis, F., Campiglio, M., Mastroianni, A., Martignone, S., Pellegrini, R., Casalini, P., Lanzi, C., Ménard, S., & Colnaghi, M. I. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910470625 · Cited by 109
Self-citationLennon, S., Barton, C. M., Banken, L., Gianni, L., Marty, M. E., Baselga, J. M., & Leyland-Jones, B. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.8351 · Cited by 103
HER2 as a target for breast cancer therapy
Tagliabue, E., Balsari, A., Campiglio, M., & Pupa, S. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003689972 · Cited by 95
Self-citationAnti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
Guarneri, V., Barbieri, E., Dieci, M. V., Piacentini, F., & Conte, P. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70022-0 · Cited by 91
Foldynová-Trantírková, S., Sekyrová, P., Tmejová, K., Brumovská, E., Bernatík, O., Blankenfeldt, W., Krejčí, P., Kozubík, A., Doležal, T., Trantírek, L., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2581 · Cited by 80
Nahta, R., Shabaya, S., Ozbay, T., & Rowe, D. (2009) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/187569209790112337 · Cited by 66
Roles of inflammation in cancer initiation progression and metastasis
Wilber, A. C. (2009) · Frontiers in Bioscience-Scholar · doi:10.2741/s55 · Cited by 65
Shed HER2 extracellular domain in HER2‐mediated tumor growth and in trastuzumab susceptibility
Ghedini, G. C., Ciravolo, V., Tortoreto, M., Giuffré, S., Bianchi, F., Campiglio, M., Mortarino, M., Figini, M., Coliva, A., Carcangiu, M. L., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22257 · Cited by 31
Self-citation
Cited by
The biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
“CD20 exosomes from B cell lymphoma act as a decoy for the binding of anti-CD20 toB cells (169), andHER2 (human epidermal growth factor receptor 2)–positive exosomes from breast cancer cells act as a decoy for anti-HER2 therapy (170), thus limiting their activity toward cancer cells.”
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
Melo, S. A., Luecke, L. B., Kahlert, C., Fernandez, A. F., Gammon, S. T., Kaye, J., LeBleu, V. S., Mittendorf, E. A., Weitz, J., Rahbari, N., et al. (2015) · Nature · doi:10.1038/nature14581 · Cited by 2,880
The biology and function of exosomes in cancer
Kalluri, R. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81135 · Cited by 1,849
Classification, Functions, and Clinical Relevance of Extracellular Vesicles
van der Pol, E., Böing, A. N., Harrison, P., Sturk, A., & Nieuwland, R. (2012) · Pharmacological Reviews · doi:10.1124/pr.112.005983 · Cited by 1,754
Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance
Mashouri, L., Yousefi, H., Aref, A. R., Ahadi, A. M., Molaei, F., & Alahari, S. K. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0991-5 · Cited by 1,363
Metadata
- Authors
- Ciravolo, V., Huber, V., Ghedini, G. C., Venturelli, E., Bianchi, F., Campiglio, M., Morelli, D., Villa, A., Mina, P. D., Menard, S., Filipazzi, P., Rivoltini, L., Tagliabue, E., & Pupa, S. M.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2011-11-23
- Volume
- 227
- Issue
- 2
- Pages
- 658-667
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W1998802762
- Cited by
- 514
- References
- 35
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.